Immuno-Oncology | Specialty

Borghaei Stresses Importance of Immunotherapy Biomarkers in Frontline Advanced NSCLC Treatment

October 26th 2020

Hossein Borghaei, DO, MS, further discusses the benefit of immunotherapy combinations, the potential of tiragolumab, and the need for better biomarkers to guide treatment in NSCLC.

Immunotherapy Investigations Lay Groundwork for Future Research Across GI Cancer Settings

October 21st 2020

Manish A. Shah, MD, FASCO, discusses key clinical trials that have evaluated the utility of pembrolizumab and nivolumab in the gastric/gastroesophageal junction cancer, and esophageal squamous cell carcinoma paradigms.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

FIP200 Deletion May Enhance Response to Immunotherapy in Breast Cancer

October 19th 2020

FIP200 deletion was found to enhance the efficacy of immune checkpoint inhibition in patients with nonresponsive breast cancer.

Immunotherapy Expert Puts Fresh Focus on AEs

October 15th 2020

In less than 10 years, immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for patients with metastatic melanoma, helping to drive an improvement in 5-year survival rates from historical levels of less than 10% to more than 50% with some regimens.

Dr. Yap on the Rationale for the SEASTAR Trial in Advanced Solid Tumors

October 8th 2020

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors

October 8th 2020

In our exclusive interview, Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in tumor mutational burden–high solid tumors, shares the “transformative importance” of the regulatory decision, and speaks to the controversy surrounding the approval.

Neoadjuvant Nivolumab/Chemo Combo Significantly Improves pCR in Resectable NSCLC

October 7th 2020

The combination of nivolumab plus chemotherapy resulted in a statistically significant improvement in pathologic complete response when used as neoadjuvant treatment in patients with resectable non–small cell lung cancer, meeting the primary end point of the phase 3 CheckMate-816 trial.

Nivolumab/Ipilimumab Elicits Durable Responses in Refractory Advanced RCC

October 6th 2020

Scott Tykodi, MD, PhD, discusses the FRACTION-RCC study and other novel combinations under exploration for heavily pretreated patients with advanced renal cell carcinoma.

2020 ISGIO Seeks to Simplify Complexities in GI Cancer to Improve Care

October 3rd 2020

Tanios S. Bekaii-Saab, MD, FACP, shares key topics covered in the 17th Annual ISGIO meeting and its significance in the ever-evolving GI cancer space.

Dr. Gerber on the Rationale to Combine Immunotherapy With Radiation in Lung Cancer

October 2nd 2020

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

FDA Approves Nivolumab/Ipilimumab for Frontline Unresectable Malignant Pleural Mesothelioma

October 2nd 2020

The FDA has approved nivolumab (Opdivo) at 360 mg every 3 weeks plus ipilimumab (Yervoy) at 1 mg/kg every 6 weeks for the frontline treatment of adult patients with unresectable malignant pleural mesothelioma.

Vokes Voices How to Use Genomics to Predict Response to Checkpoint Inhibitors in Cancer

September 26th 2020

Natalie I. U. Vokes, MD, discusses the rise of predictive genomic biomarkers in oncology.

Adjuvant Nivolumab Improves DFS in High-Risk Muscle-Invasive Urothelial Carcinoma

September 25th 2020

Adjuvant nivolumab was found to result in a significant improvement in disease-free survival compared with placebo in patients with high-risk muscle-invasive urothelial carcinoma, including those whose tumors expressed PD-L1 of 1% or higher, meeting the primary end points of the phase 3 CheckMate-274 trial.

Dr. Lwin on the Results of the LEAP-005 Trial in Advanced Solid Tumors

September 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the results of the LEAP-005 trial in advanced solid tumors.

First-in-Human Study of RO7122290 Shows Promise in Patients With Select Solid Tumors

September 19th 2020

Safety and preliminary antitumor activity with the bispecific antibody RO7122290 alone or in combination with atezolizumab demonstrated preliminary antitumor activity and was safe for the treatment of patients with advanced solid tumors.

PD-L1 Status Guides TIL activity in NeoTRIPaPDL1

September 19th 2020

Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.

Preclinical Data Suggest Novel Molecule Enhances Immunotherapy Response in CRC

September 17th 2020

Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.

Bispecific Antibody CDX-527 Enters Phase 1 Trial in Solid Tumors

September 16th 2020

The bispecific antibody CDX-527 is now under investigation in patients with advanced or metastatic solid tumors who have progressed during or following standard-of-care treatment with the recent initiation of a open-label phase 1 trial.

ALKS 4230 Under Exploration for Advanced Malignant Solid Tumors in ARTISTRY-3 Trial

September 15th 2020

Investigators are evaluating the clinical and immunological impact of the experimental, engineered fusion protein ALKS 4230 on the tumor microenvironment of several advanced, malignant solid tumors in the recently initiated phase 2 ARTISTRY-3 trial.